Arbutus Biopharma Corporation
Price Action
Technical Summary
WEAKENINGArbutus Biopharma Corporation is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is moderate (RS Rating: 63), indicating performance broadly in line with the market. Earnings growth of 8% provides fundamental context to the price action. A decisive close above the 200-day moving average is required to signal a potential trend reversal.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.48 | +10.97% | ABOVE |
| 50 SMA | $4.40 | +12.95% | ABOVE |
| 100 SMA | $4.41 | +12.65% | ABOVE |
| 150 SMA | $4.42 | +12.41% | ABOVE |
| 200 SMA | $4.43 | +12.25% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ABUS in an uptrend right now?
ABUS has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is ABUS overbought or oversold?
ABUS's RSI (14) is 67. The stock is in neutral territory, neither overbought nor oversold.
Is ABUS outperforming the market?
ABUS has a Relative Strength (RS) Rating of 63 out of 99. ABUS is performing about average compared to the market.
Where is ABUS in its 52-week range?
ABUS is trading at $4.97, which is 97% of its 52-week high ($5.10) and 94% above its 52-week low ($3.08).
How volatile is ABUS?
ABUS has a Beta of 1.35 and 52-week volatility of 46%. It's more volatile than the S&P 500 - expect bigger swings.